bluebird bio Completes Acquisition by Carlyle and SK Capital

bluebird bio, a pioneering biotherapeutics company in gene therapies for severe genetic diseases, has been acquired by global investment firms Carlyle and SK Capital. The acquisition marks the end of bluebird's publicly traded status as its common stock ceases trading. With this transaction, bluebird receives a substantial capital infusion aimed at enhancing its commercial delivery for patients suffering from conditions such as sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. New CEO David Meek, along with a team of seasoned executives, is set to lead bluebird into a new era that focuses on expanding manufacturing capabilities and improving the treatment experience for patients. Carlyle and SK Capital express their commitment to leveraging their collective expertise to fulfill bluebird's potential and increase patient access to its innovative therapies. The firms, which manage multibillion-dollar portfolios, are optimistic about the growth prospects this partnership holds for bluebird bio.